Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Tirzepatide, a dual GIP/GLP-1 receptor agonist approved by the FDA for diabetes management and chronic weight management, works by enhancing insulin secretion, suppressing glucagon, and reducing appetite
GLP-1, GLP-1 Probiotic, Pendulum - ,
Similar patterns were observed for SGLT-2 inhibitors during the initial exposed period (0-12 months) and the late exposed period (13-24 months)
For tirzepatide (Zepbound) Jastreboff and colleagues reported in the New England Journal of Medicine in 2022 that at maximal doses, the percent of individuals reporting side effects were as follows: Nausea 31.0% Diarrhea 23.0% Vomiting 12.2% Constipation 11.7% Bettge and colleagues conducted a study published in Diabetes, Obesity, and Metabolism in 2017 that showed that individuals who were taking metformin while taking a GLP-1 were more likely to have side effects, especially nausea and vomiting
The fix: Gradually increase fiber to 25-38g daily
US$ 24.81
US$ 28.87
US$ 20.44
US$ 20.22
US$ 28.61
US$ 21.68
US$ 28.23
US$ 22.09
US$ 20.36
US$ 23.85
US$ 24.34
US$ 23.58
US$ 23.84
